EUVIMEDEUVIMED entdecken
Open Access

A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy

Marina E Kirkland iD, Stephanie Patfield, Anna C Hughes, Bradley Hernlem, Xiaohua He iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00598-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Marina E Kirkland und 4 weiteren Autor:innen. Beteiligte Einrichtung: United States Department of Agriculture, Agricultural Research Service, Western Regional Research Center , Albany, California, USA. Hauptthemen laut MEDLINE: Escherichia coli Infections, Shiga-Toxigenic Escherichia coli, Hemolytic-Uremic Syndrome. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: U.S. Department of Agriculture (USDA), U.S. Department of Energy (DOE).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Shiga toxin-producing Escherichia coli infections are difficult to treat due to the risk of antibiotic-induced stress upregulating the production of toxins, medical treatment is consequently limited to supportive care to prevent the development of hemolytic uremic syndrome (HUS). Here, we introduce a potentially therapeutic humanized mouse monoclonal antibody (Hu-mAb 2-5) targeting Stx2a, the most common Shiga toxin subtype identified from outbreaks. We demonstrate that Hu-mAb 2-5 has low immunogenicity in healthy adults ex vivo and high neutralizing efficacy in vivo , protecting mice from mortality and HUS-related tissue damage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coli InfectionsShiga-Toxigenic Escherichia coliHemolytic-Uremic SyndromeHumansAdultAnimalsMiceShiga ToxinShiga Toxin 2Antibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Shiga toxinsantibacterial therapeuticsexperimental therapeuticsmonoclonal antibodies

Substanzen

Shiga ToxinShiga Toxin 2Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • United States Department of Agriculture, Agricultural Research Service, Western Regional Research Center , Albany, California, USA.
  • U.S. Department of Energy, Oak Ridge Institute for Science and Education , Oak Ridge, Tennessee, USA.

ORCID-Profile: Marina E Kirkland, Xiaohua He

Förderung

  • U.S. Department of Agriculture (USDA)
  • U.S. Department of Energy (DOE)

Zitieren

APA

Kirkland, M. E., Patfield, S., Hughes, A. C., Hernlem, B., & He, X. (2024). A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00598-23

Vancouver

Kirkland ME, Patfield S, Hughes AC, Hernlem B, He X. A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00598-23

BibTeX
@article{Kirkland2024,
  author = {Kirkland, Marina E and Patfield, Stephanie and Hughes, Anna C and Hernlem, Bradley and He, Xiaohua},
  title = {A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00598-23}
}
Kostenlos starten →